Page last updated: 2024-10-16

carnitine and Attention Deficit Disorder with Hyperactivity

carnitine has been researched along with Attention Deficit Disorder with Hyperactivity in 3 studies

Attention Deficit Disorder with Hyperactivity: A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)

Research Excerpts

ExcerptRelevanceReference
"Treatment with carnitine significantly decreased the attention problems and aggressive behavior in boys with ADHD."2.70Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. ( Scholte, HR; Van Oudheusden, LJ, 2002)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Qutob, HMH1
Saad, RA1
Bali, H1
Osailan, A1
Jaber, J1
Alzahrani, E1
Alyami, J1
Elsayed, H1
Alserihi, R1
Shaikhomar, OA1
Divya, KM1
Savitha, DP1
Krishna, GA1
Dhanya, TM1
Mohanan, PV1
Shah, SF1
Jafry, AT1
Hussain, G1
Kazim, AH1
Ali, M1
Rivani, E1
Endraswari, PD1
Widodo, ADW1
Khalil, MR1
Guldberg, R1
Nørgård, BM1
Uldbjerg, N1
Wehberg, S1
Fowobaje, KR1
Mashood, LO1
Ekholuenetale, M1
Ibidoja, OJ1
Romagnoli, A1
D'Agostino, M1
Pavoni, E1
Ardiccioni, C1
Motta, S1
Crippa, P1
Biagetti, G1
Notarstefano, V1
Rexha, J1
Perta, N1
Barocci, S1
Costabile, BK1
Colasurdo, G1
Caucci, S1
Mencarelli, D1
Turchetti, C1
Farina, M1
Pierantoni, L1
La Teana, A1
Al Hadi, R1
Cicconardi, F1
Chinappi, M1
Trucchi, E1
Mancia, F1
Menzo, S1
Morozzo Della Rocca, B1
D'Annessa, I1
Di Marino, D1
Choya, A1
de Rivas, B1
Gutiérrez-Ortiz, JI1
López-Fonseca, R1
Xu, S1
Cheng, B1
Huang, Z1
Liu, T1
Li, Y1
Jiang, L1
Guo, W1
Xiong, J1
Amirazodi, M1
Daryanoosh, F1
Mehrabi, A1
Gaeini, A1
Koushkie Jahromi, M1
Salesi, M1
Zarifkar, AH1
Studeny, P1
Netukova, M1
Nemcokova, M1
Klimesova, YM1
Krizova, D1
Kang, H1
Tao, Y1
Zhang, Q1
Sha, D1
Chen, Y1
Yao, J1
Gao, Y1
Liu, J1
Ji, L1
Shi, P1
Shi, C1
Wu, YL1
Wright, AI1
M El-Metwaly, N1
A Katouah, H1
El-Desouky, MG1
El-Bindary, AA1
El-Bindary, MA1
Kostakis, ID1
Raptis, DA1
Davidson, BR1
Iype, S1
Nasralla, D1
Imber, C1
Sharma, D1
Pissanou, T1
Pollok, JM1
Hughes, AM1
Sanderson, E1
Morris, T1
Ayorech, Z1
Tesli, M1
Ask, H1
Reichborn-Kjennerud, T1
Andreassen, OA1
Magnus, P1
Helgeland, Ø1
Johansson, S1
Njølstad, P1
Davey Smith, G1
Havdahl, A1
Howe, LD1
Davies, NM1
Amrillah, T1
Prasetio, A1
Supandi, AR1
Sidiq, DH1
Putra, FS1
Nugroho, MA1
Salsabilla, Z1
Azmi, R1
Grammatikopoulos, P1
Bouloumis, T1
Steinhauer, S1
Mironov, VS2
Bazhenova, TA2
Manakin, YV2
Yagubskii, EB2
Yakushev, IA1
Gilmutdinov, IF1
Simonov, SV1
Lan, K1
Yang, H1
Zheng, J1
Hu, H1
Zhu, T1
Zou, X1
Hu, B1
Liu, H1
Olokede, O1
Wu, H1
Holtzapple, M1
Gungor, O1
Kose, M1
Ghaemi, R1
Acker, M1
Stosic, A1
Jacobs, R1
Selvaganapathy, PR1
Ludwig, N1
Yerneni, SS1
Azambuja, JH1
Pietrowska, M1
Widłak, P1
Hinck, CS1
Głuszko, A1
Szczepański, MJ1
Kärmer, T1
Kallinger, I1
Schulz, D1
Bauer, RJ1
Spanier, G1
Spoerl, S1
Meier, JK1
Ettl, T1
Razzo, BM1
Reichert, TE1
Hinck, AP1
Whiteside, TL1
Wei, ZL1
Juan, W1
Tong, D1
Juan, LX1
Sa, LY1
Jie, HFM1
Xiao, G1
Xiang, LG1
Jie, HM1
Xu, C1
Yu, DN1
Yao, ZX1
Bigdeli, F1
Gao, XM1
Cheng, X1
Li, JZ1
Zhang, JW1
Wang, W2
Guan, ZJ1
Bu, Y1
Liu, KG1
Morsali, A1
Das, R1
Paul, R1
Parui, A1
Shrotri, A1
Atzori, C1
Lomachenko, KA1
Singh, AK1
Mondal, J1
Peter, SC1
Florimbio, AR1
Coughlin, LN1
Bauermeister, JA1
Young, SD1
Zimmerman, MA1
Walton, MA1
Bonar, EE1
Demir, D1
Balci, AB1
Kahraman, N1
Sunbul, SA1
Gucu, A1
Seker, IB1
Badem, S1
Yuksel, A1
Ozyazicioglu, AF1
Goncu, MT1
Zhang, H1
Zhou, H1
Deng, Z1
Luo, L1
Ong, SP1
Wang, C1
Xin, H1
Whittingham, MS1
Zhou, G1
Maemura, R1
Wakamatsu, M1
Matsumoto, K1
Sakaguchi, H1
Yoshida, N1
Hama, A1
Yoshida, T1
Miwata, S1
Kitazawa, H1
Narita, K1
Kataoka, S1
Ichikawa, D1
Hamada, M1
Taniguchi, R1
Suzuki, K1
Kawashima, N1
Nishikawa, E1
Narita, A1
Okuno, Y1
Nishio, N1
Kato, K1
Kojima, S1
Morita, K1
Muramatsu, H1
Takahashi, Y1
Yirgu, A1
Mekonnen, Y1
Eyado, A1
Staropoli, A1
Vinale, F1
Zac, J1
Zac, S1
Pérez-Padilla, R1
Remigio-Luna, A1
Guzmán-Boulloud, N1
Gochicoa-Rangel, L1
Guzmán-Valderrábano, C1
Thirión-Romero, I1
Statsenko, ME1
Turkina, SV1
Barantsevich, ER1
Karakulova, YV1
Baranova, NS1
Morzhukhina, MV1
Wang, Q1
Gu, Y1
Chen, C1
Qiao, L1
Pan, F1
Song, C1
Canetto, SS1
Entilli, L1
Cerbo, I1
Cipolletta, S1
Wu, Y2
Zhu, P1
Jiang, Y1
Zhang, X1
Wang, Z1
Xie, B1
Song, T1
Zhang, F1
Luo, A1
Li, S1
Xiong, X1
Han, J1
Peng, X1
Li, M1
Huang, L1
Chen, Q1
Fang, W1
Hou, Y1
Zhu, Y1
Ye, J1
Liu, L1
Islam, MR1
Sanderson, P1
Johansen, MP1
Payne, TE1
Naidu, R1
Cao, J1
Yang, J1
Niu, X1
Liu, X1
Zhai, Y1
Qiang, C1
Niu, Y1
Li, Z1
Dong, N1
Wen, B1
Ouyang, Z1
Zhang, Y1
Li, J2
Zhao, M1
Zhao, J1
Morici, P1
Rizzato, C1
Ghelardi, E1
Rossolini, GM1
Lupetti, A1
Gözüküçük, R1
Cakiroglu, B1
He, X1
Li, R1
Zhao, D1
Zhang, L1
Ji, X1
Fan, X1
Chen, J1
Wang, Y1
Luo, Y1
Zheng, D1
Xie, L1
Sun, S1
Cai, Z1
Liu, Q1
Ma, K1
Sun, X1
Drinkwater, JJ1
Davis, TME1
Turner, AW1
Davis, WA1
Suzuki, Y1
Mizuta, Y1
Mikagi, A1
Misawa-Suzuki, T1
Tsuchido, Y1
Sugaya, T1
Hashimoto, T1
Ema, K1
Hayashita, T1
Santos-Cubiñá, J1
Torres-Rodríguez, A1
Castaing-Lespier, PA1
Sabaté, N1
Torres-Martin, A1
Carlo, S1
Van Oudheusden, LJ1
Scholte, HR1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940]Phase 3120 participants (Actual)Interventional2018-05-28Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for carnitine and Attention Deficit Disorder with Hyperactivity

ArticleYear
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022

Trials

2 trials available for carnitine and Attention Deficit Disorder with Hyperactivity

ArticleYear
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022
Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder.
    Prostaglandins, leukotrienes, and essential fatty acids, 2002, Volume: 67, Issue:1

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carnitine; Child; Child Behavior; Cross-O

2002

Other Studies

1 other study available for carnitine and Attention Deficit Disorder with Hyperactivity

ArticleYear
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.
    Boletin de la Asociacion Medica de Puerto Rico, 2013, Volume: 105, Issue:3

    Topics: Adult; Antidepressive Agents; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Benzo

2013